CD274 and non-small cell lung carcinoma: For example, in a recent CITYSCAPE phase 2 trial, anti-TIGIT, tiragolumab when combined with anti-PD-L1, atezolizumab resulted in a significant benefit in PFS and ORR in PD-L1-positive metastatic NSCLC patients compared to anti-PD-L1 monotherapy [99].